细菌性疾病诊断市场
细菌性疾病诊断市场：2026年市场规模约为40.6亿美元，2031年市场规模约为58.8亿美元；预测期复合年增长率为7.70%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
细菌性疾病诊断市场：2026年市场规模约为40.6亿美元，2031年市场规模约为58.8亿美元；预测期复合年增长率为7.70%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 7.7% | 机构预测 |
| 市场规模 | 2026 | USD 4.06 billion | 机构预测 |
| 市场规模 | 2031 | USD 5.88 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| disease_and_clinical_application | respiratory bacterial diseases | 2025 | 32.880% |
| end_user | hospitals and ambulatory surgical centers | 2025 | 55.450% |
| geography | North America | 2025 | 42.440% |
| product_type | instruments | 2025 | 52.560% |
| sample_type | blood, serum, and plasma | 2025 | 38.660% |
| technology | PCR and real-time PCR | 2025 | 37.560% |
关键结论
- disease_and_clinical_application 维度中，respiratory bacterial diseases 在 2025 年的公开份额为 32.88%。
- end_user 维度中，hospitals and ambulatory surgical centers 在 2025 年的公开份额为 55.45%。
- geography 维度中，North America 在 2025 年的公开份额为 42.44%。
- product_type 维度中，instruments 在 2025 年的公开份额为 52.56%。
- sample_type 维度中，blood, serum, and plasma 在 2025 年的公开份额为 38.66%。
- technology 维度中，PCR and real-time PCR 在 2025 年的公开份额为 37.56%。
主要参与者
- Abbott Laboratories
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Siemens Healthineers AG
- bioMérieux SA
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising antimicrobial resistance and targeted therapy needs | +1.800% | Global, with higher intensity in South Asia, Sub-Saharan Africa, and Southern Europe | Long term (≥ 4 years) |
| Faster sepsis and bloodstream infection decisions | +1.500% | Global, with North America and Europe leading adoption and Asia-Pacific scaling rapidly | Medium term (2-4 years) |
| Multiplex molecular and syndromic testing expansion | +1.300% | North America and Europe, with growing adoption in Asia-Pacific and the Middle East and Africa | Medium term (2-4 years) |
| Public investment in bacteriology and AMR surveillance | +0.800% | Global, with concentration in low- and middle-income countries and G7-backed programs | Long term (≥ 4 years) |
| Testing decentralization to near-patient settings | +1.000% | North America, Western Europe, India, and Southeast Asia | Short term (≤ 2 years) |
| Digital, automated, and ai-assisted microbiology workflows | +0.800% | North America and Europe, with increasing domestic integration in China | Medium term (2-4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Reimbursement and laboratory budget pressure | -0.600% | North America and Europe | Short term (≤ 2 years) |
| Resistance gene and phenotypic susceptibility discordance | -0.400% | Global, with stronger effects in Asia-Pacific and low- and middle-income countries | Long term (≥ 4 years) |
| Pre-analytical variability and low pathogen loads | -0.300% | Global | Medium term (2-4 years) |
| Fragmented regulation and breakpoint updates | -0.300% | Asia-Pacific, Latin America, and the Middle East and Africa | Long term (≥ 4 years) |
报告关注的关键问题
What is the projected value of bacterial disease diagnostics by 2031?
The bacterial disease diagnostics market is projected to reach USD 5.88 billion by 2031, growing at a 7.70% CAGR from 2026.
What is driving growth in bacterial testing?
Antimicrobial resistance, faster sepsis decisions, multiplex testing, and wider use of point-of-care systems are supporting demand.
Which product segment leads bacterial disease diagnostics?
Instruments led with a 52.56% share in 2025, supported by hospital investments in automated blood culture, molecular, and MALDI-TOF platforms.
Which technology is growing fastest for bacterial testing?
Rapid point-of-care technology is forecast to grow at an 8.80% CAGR through 2031 as testing moves closer to emergency and critical care settings.
Why are bloodstream infection tests becoming more important?
Bloodstream infections and sepsis are forecast to grow at a 9.56% CAGR because clinicians need faster pathogen and resistance information for urgent treatment decisions.
Which region is growing fastest in bacterial disease diagnostics?
Asia-Pacific is forecast to grow at a 10.88% CAGR through 2031, supported by expanding intensive care infrastructure, sepsis programs, and molecular laboratory investment.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence